<DOC>
	<DOCNO>NCT02766803</DOCNO>
	<brief_summary>Polycystic ovary syndrome ( PCOS ) common endocrinopathy affect woman reproductive age . Hyperandrogenism central feature PCOS . Studies isolated ovarian theca-interstitial cell indicate resveratrol , natural polyphenol , reduce androgen production . This study design evaluate endocrine metabolic effect simvastatin resveratrol PCOS . Methods : A randomize ( 1:1 ) double-blind , placebo-controlled trial evaluate effect administer 20 mg simvastatin daily 500 mg resveratrol daily , administer 20 mg simvastatin placebo woman PCOS academic hospital . PCOS define accord Rotterdam criterion . Evaluations perform baseline repeat 3 6 month treatment . The main outcome change serum total testosterone fast insulin level .</brief_summary>
	<brief_title>Effects Simvastatin Micronized Trans-resveratrol Treatment Polycystic Ovary Syndrome ( PCOS ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Resveratrol</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>PCOs insulin resistance normal prolactin , TSH , 17 OH progesterone No evidence androgen produce malignancy , Cushing 's syndrome acromegaly use oral contraceptive and/or steroid hormone 3 month prior study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>